Testicular cancer historical perspective

Testicular cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Testicular cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Testicular cancer historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Testicular cancer historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Testicular cancer historical perspective

CDC on Testicular cancer historical perspective

Testicular cancer historical perspective in the news

Blogs on Testicular cancer historical perspective

Directions to Hospitals Treating Testicular cancer

Risk calculators and risk factors for Testicular cancer historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Gertrude Djouka, M.D.[2]

## Overview[edit | edit source]

There is a limited information about the historical perspective of testicular germ cell tumors. Leydig cells were first discovered by Franz Leydig who was a German anatomist in 1870.

## Historical Perspective[edit | edit source]

### Discovery[edit | edit source]

* There is a limited information about the historical perspective of testicular tumors. Leydig cells were first discovered by Franz Leydig who was a German anatomist in 1870.[1]

### Landmark Events in the Development of Treatment Strategies[edit | edit source]

* In 1965, Dr. Barnett Rosenberg, a biophysics research at Michigan State University, discovered cisplatin drug which affects the cells division. The blockage of cell division was from the platinum found in the electrodes. The experiment was tested in the mice at low dose of cisplatin since cisplatin at high doses might cause renal toxicities.[2][3]
* In 1972, National Cancer Institute stepped in and participated in the funding of the clinical trials in human patients with advanced testicular cancers under the supervision of Dr. lawrence Einhorn at Indiana University.
* In 1978, Food and Drugs Administration (FDA) approved cisplatin drug for the treatment of testicular cancer based on successful clinical trials. Cisplatin has improved the lives of many patients diagnosed with testicular cancers and others when combining with others drugs.[4]

## References[edit | edit source]

1. ↑ Al-Agha OM, Axiotis CA (February 2007). "An in-depth look at Leydig cell tumor of the testis". Arch. Pathol. Lab. Med. 131 (2): 311–7. doi:10.1043/1543-2165(2007)131[311:AILALC]2.0.CO;2. PMID 17284120.
2. ↑ "Discovery – Cisplatin and The Treatment of Testicular and Other Cancers - National Cancer Institute, The "Accidental" Cure—Platinum-based Treatment for Cancer: The Discovery of Cisplatin".
3. ↑ Nakamura T, Miki T (February 2010). "Recent strategy for the management of advanced testicular cancer". Int. J. Urol. 17 (2): 148–57. doi:10.1111/j.1442-2042.2009.02431.x. PMID 20377835.
4. ↑ Gómez-Ruiz S, Maksimović-Ivanić D, Mijatović S, Kaluđerović GN (2012). "On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapy". Bioinorg Chem Appl. 2012: 140284. doi:10.1155/2012/140284. PMC 3401524. PMID 22844263.

Template:WH Template:WS